12:00 AM
 | 
Mar 18, 2013
 |  BC Week In Review  |  Company News  |  Deals

Cubist, Astellas deal

Cubist acquired rights to the cephalosporin antibiotic ceftolozane in undisclosed Asia-Pacific and Middle East territories from Astellas. The pharma will receive $25 million up front and sales of ceftolozane/tazobactam ( CXA-201) in the newly obtained territories will be counted towards commercial milestones and royalty terms of the companies' original agreement. According to...

Read the full 255 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >